Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era

A. Deyà-Martínez a,b,c,d,*, A. García-García a,b,c,d, E.A. Gonzalez-Navarro d,f, L. Yiyi b,d, A. Vlagea a,f, I. Jordan c,h,i,k, V. Fumadó c,h,i,k, C. Fortuny c,g,i,k, M. Español d,i, C. Launes c,i,k, A. Esteve-Sole a,b,d, M. Juan d,e,f, M. Pascal d,f,m,2, L. Alsina a,b,c,d,e,*

A. Study Group for Immune Dysfunction Diseases in Children (GEMDIP), Institut de Recerca Sant Joan de Déu, Barcelona, Spain
b Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain
c Universitat de Barcelona, Spain
d Clinical Immunology Program, Hospital Sant Joan de Déu-Hospital Clinic Barcelona, Barcelona, Spain
e Immunotherapy Platform, Hospital Sant Joan de Déu-Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
f Department of Immunology-CDB, Hospital Clinic-IDIBAPS, Universitat de Barcelona, Barcelona, Spain
g Paediatric Infectious Diseases Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
h Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
i Institut de Recerca Sant Joan de Déu, Barcelona, Spain
j Paediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain
k CIBER of Epidemiology and Public Health, Madrid, Spain
l Spanish Network for Allergy - RETIC de Asma, Reacciones adversas y Alérgicas (ARADYAL), Madrid, Spain

A R T I C L E   I N F O
Keywords:
Primary immunodeficiency disease
Inborn errors immunity
Children, COVID-19

A B S T R A C T
Background: Information regarding inborn error of immunity (IEI) as a risk factor for severe COVID-19 is scarce. We aimed to determine if paediatric patients with moderate/severe IEI got COVID-19 at the same level as the general population, and to describe COVID-19 expression.

Material and methods: We included patients with moderate/severe IEI aged 0–21 years old: cross-sectional study (June 2020) to determine the prevalence of COVID-19; prospective study (January 2020–January 2021) including IEI patients with COVID-19. Assays used: nasopharyngeal swab SARS-CoV-2 PCR and SARS-CoV-2-specific immunoglobulins.

Results: Seven from sixty-five patients tested positive (prevalence: 10.7% (7–13%)) after the first SARS-COV-2 wave and 13/15 patients diagnosed with COVID-19 had an asymptomatic/mild course.

Conclusions: In our area, prevalence of COVID-19 in moderate/severe IEI paediatric patients after the first wave was slightly higher than in the general population. The majority of patients presented a benign course, suggesting a possible protective factor related with age despite IEI.

Abbreviations: ACE-II, angiotensin-converting enzyme II; CGD, chronic granulomatous disease; CID, combined immunodeficiency; CMC, chronic mucocutaneous candidiasis; CVID, common variable immunodeficiency; ESSID, European Society of Immunodeficiencies; HSCT, hematopoietic stem cell transplant; IEI, inborn errors of immunity; IgRT, immunoglobulin replacement treatment; PBMC, peripheral blood mononuclear cells; PBL, peripheral blood lymphocytes; PBS, phosphate-buffered saline; PHA, phytohemagglutinin; RT-PCR, real-time-PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCID, severe combined immunodeficiency; TMB, tetramethylbenzidine; WHIM, (warts, hypogammaglobulinemia, immunodeficiency, myelokathexis); WHO, World Health Organization.

* Corresponding authors at: Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu 2, 08950 Barcelona, Spain.
E-mail addresses: adeya@sjdhospitalbarcelona.org (A. Deyà-Martínez), mpascal@clinic.cat (M. Pascal), lalsina@sjdhospitalbarcelona.org (L. Alsina).

1 Dra Angela Deyà-Martínez is co-corresponding author with Dra Laia Alsina.
2 Dra Martina Pascal is co-senior author with Dra Laia Alsina.

https://doi.org/10.1016/j.clim.2021.108821
Received 3 July 2021; Received in revised form 2 August 2021; Accepted 6 August 2021
Available online 12 August 2021
1521-6616/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

In December 2019, an outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, leading to a pandemic of a novel coronavirus disease (COVID-19) [1–3]. After the first COVID-19 case in Spain, reported on 31st January 2020 in La Gomera (Canary Islands), more than 3 million cases [4] of SARS-CoV-2-infected patients had been reported in our country by the end of April 2021, and more specifically >650,000 cases [5] in our region, Catalonia.

In children, a milder course of COVID-19 compared with adults has been reported worldwide [1] with a very low proportion of symptomatic paediatric patients progressing to acute respiratory distress syndrome or multiorgan system dysfunction [6,7].

The main factors related to critical cases are age (>65), male gender, and the presence of certain comorbidities such as diabetes, hypertension, chronic respiratory disease, cancer, and cardiovascular disease [8,9].

Although inborn errors of immunity (IEI) have been assumed to be a risk factor for COVID-19, there is as yet limited information, mainly from adults, and often contradictory at that, about the real impact of COVID-19 on them. Recent studies suggest that only certain IEIs may predispose to severe COVID-19, whereas others could represent a protective factor [10–16]. Nevertheless, reports on paediatric IEI patients are still scarce.

The objectives of the study were first to determine, through a prevalence study, whether children and young adults with moderate/severe IEI living in a high burden area of SARS-CoV-2 infection became infected at the same level as the general population in the first wave, and, second, to describe their clinical presentation of SARS-CoV-2 infection prior to the vaccination era.

2. Material and methods

The study was carried out in a tertiary centre dedicated exclusively to maternal and child healthcare in Barcelona, Catalonia (population > 7.5 million), Spain, with 314-bed facility, 247,000 outpatient visits per year from all paediatric subspecialties and reference for IEI, attending more than 400 IEI patients. The first wave occurred January-June 2020. Lockdown extended from March 15th to June 21st.

The study design is detailed in Appendices Fig. A.1, with two different periods: 1) a cross-sectional study (prevalence study) in June 2020 (end of first wave) including all moderate/severe IEI patients followed in our Clinical Immunology and Primary Immunodeficiencies Unit who agreed to participate, and 2) a prospective study including all IEI patients in follow-up evaluated for SARS-CoV-2 infection from January 2020 until January 2021 (start of vaccination), collecting clinical and laboratory data of COVID-19 infection. The protocol of this study was reviewed and approved by the ethics committee of our institution. Patients aged 0–21 years old with signed informed consent were included.

COVID-19 cases were defined according to World Health Organization (WHO) criteria [17]. The different IEI categories were based on European Society for Immunodeficiencies (ESID) criteria [18]. The following were considered moderate/severe IEI: severe combined immunodeficiencies, combined immunodeficiencies and other combined immunodeficiencies with syndromic features with moderate/severe lymphopenia (see definition in Appendices Table A.2) [19], severe humoral immunodeficiencies (common variable immunodeficiency (CVID) and agammaglobulinemia), and genetically well-defined and severe cases from other IEI groups.

Patients’ clinical and laboratory data were collected from medical charts during the outpatient visit. A specific questionnaire related to COVID-19 in household contacts was used.

The following assays were performed in all patients to confirm SARS-CoV-2 infection: 1) Real-time (RT)-PCR with nasopharyngeal swab. Viral RNA extraction was performed with NucliSENS easyMAG.

Table 1
Baseline characteristics of the IEI cohort included in the study.

| Comorbidity                         | N  | N (%) |
|-------------------------------------|----|-------|
| Respiratory disease                 | 4/65| (6.1%)|
| Cardiovascular disease              | 4/65| (6.1%)|
| Hemato-oncological disease          | 3/65| (4.6%)|
| Neurological disease                | 18/65| (27.7%)|
| Rheumatological diseases            | 1/65| (1.5%)|
| Treatments received from Jan-June 2020 | 48/65| (75.9%)|
| Antibiotic treatment                | 19/65| (29.2%)|
| Antiviral treatment                 | 3/65| (4.6%)|
| Antifungal treatment                | 8/65| (12.3%)|
| Hydroxychloroquine                  | 1/65| (1.5%)|
| Steroids /immunosuppressants잁 | 10/65| (15.4%)|
| Group of IEI                         |    |       |
| Immunodeficiencies affecting cellular and humoral immunity | 7/65| (10.7%)|
| CID with associated syndromic features | 31/65| (47.7%)|
| Predominantly antibody deficiencies | 14/65| (20.6%)|
| Diseases of immune dysregulation    | 4/65| (6.1%)|
| Congenital defects of phagocyte number, function, or both | 2/65| (3.1%)|
| Defects of intrinsic and innate immunity | 6/65| (9.2%)|
| Auto-inflammation disorders         | 1/65| (1.5%)|

COVID-19 epidemiological, clinical and diagnostic information

Confirmed COVID-19 cases in cohabiting relatives 1/65 (1.5%)
Suspicion of COVID-19 in cohabiting relatives 10/65 (15.1%)
Needs emergency from Jan-June 2020 19/65 (29.2%)
Felt sick from January-June 30/65 (46.1%)
Respiratory infectiona | 23/65| (35.4%)|
Gastrointestinal infection | 8/65| (12.3%)|
Cutaneous lesionsd | 8/65| (12.3%)|
Appendicitis | 0/65| (0%)|
Invasive infectione | 7/65| (10.8%)|
Positive SARS-CoV-2 PCR 0/65 (0)
Positive SARS-CoV-2 serology
IgG + IgA | 2/65| (3.1%)|
IgA | 2/65| (3.1%)|
IgM | 1/65| (1.5%)|
IgG | 2/65| (3.1%)|

CID: combined immunodeficiency.
a Data are expressed as (median (min-max) and percentage).
b Immunosuppressants used in the PID cohort: mofetil mycophenolate, rapamycin, azathioprine, abatacept.
c Respiratory infections: influenza-like syndrome with fever >37 °C, cough without fever, otitis, pneumonia, bronchitis, and others.
d Cutaneous lesions: urticaria, pityriasis, papular exanthema.
e Invasive infections: sepsis (3), bacterial pneumonia (2), osteoarticular infection (1), and others (1).

(BioMerieux Laboratories) or MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific) following the manufacturers’ instructions. RT-PCR was performed with the COVID-19 Plus RealAmp Kit (Genefinder Laboratories) for detection of the RdRp, E, and N viral genes and the human RNase P gene as internal control; 2) SARS-CoV-2 serology: IgG, IgA, and IgM SARS-CoV-2-specific antibodies were determined by Luminex system against the receptor-binding domain of SARS-CoV-2.
the spike glycoprotein, as reported previously. Briefly, 10 μL of plasma was incubated with antigen-coupled beads for 2 h at room temperature with agitation. Plates were then washed 3 times and incubated with a biotinylated secondary antibody (IgM, IgA, or IgG; Sigma-Aldrich) for 45 min at room temperature and with agitation. Plates were washed 3 times and streptavidin-R-phycocerythrin (Sigma-Aldrich) was added for 30 min at room temperature and with agitation. Plates were washed 3 times and beads were resuspended in phosphate-buffered saline (PBS). Plates were read using a Luminex xMAP 100 analyzer; positive values were assigned with MFI ratio 2 SD higher to a serum pool from pre-COVID pandemic samples.

2.1. Statistical analysis

Categorical and continuous variables were described as percentages and median values with ranges (min-max). For the comparative analysis, Chi-square test and Mann-Whitney U test were applied, as appropriate, for the data set. Pearson and Spearman tests were used to identify correlations between quantitative variables. The analysis was carried out using SPSS version 15.0 software (SPSS Inc., Chicago, IL), and statistical significance was set at \( P \leq 0.05 \).

3. Results

3.1. Cross-sectional study: Prevalence of SARS-CoV-2 infection in IEI patients after the first wave (June 2020)

Of the 76 patients selected with moderate/severe IEI from our cohort, 65 agreed to participate. The baseline characteristics of the cohort are detailed in Table 1 and Table A.1. The median age at the time of the study was 12.9 years old (2–21.1), 47.1% (28/65) were female, and the predominant IEI group was combined immunodeficiency with associated syndromic features (47.7%), followed by predominantly antibody deficiencies (20.6%). Seventy-three percent of the patients received some treatment from January to June 2020: 15.4% immunosuppressants (moftetil mycophenolate, rapamycin, azathioprine, abatacept, or steroids) and 21.5% regular immunoglobulin replacement treatment (IgRT).

Sixteen percent of the patients were exposed to confirmed/suspected COVID-19 cohabiting relatives (not all tested for SARS-CoV-2, due to the limited testing during the first wave of the pandemic in Spain). A total of 7 IEI patients were confirmed as having been infected with SARS-CoV-2 by means of SARS-CoV-2 serologies (7/7) (Table 1), which represents a prevalence of 10.7% (7/65).

3.2. Prospective study: Clinical expression of COVID-19 in IEI patients

Prior to the vaccination era (that is, January 2020 – January 2021), a total of 15 IEI patients were confirmed as infected by SARS-CoV-2: 2/15 by positive PCR and 13/15 by positive serologies with/without positive PCR. Of these positive patients, 60% (9/15) presented some degree of clinical expression, 7/9 mainly mild symptoms including headache, low fever, flu-like syndrome, cough, upper airway congestion, odynophagia or taste and smell disturbances; and 2/9 required admission to hospital with interstitial pneumonia. The two admitted patients were siblings with MyD88 deficiency. The main characteristics of these 2 patients and of the COVID-19 episode are depicted in Appendices Fig. A.2.

4. Discussion

The present study was designed to analyse the prevalence of SARS-CoV-2 infection in a cohort of children and young adults with moderate/severe IEI; and it describes the main clinical characteristics of COVID-19 in this paediatric cohort prior to the vaccination era. Our results reveal an infection rate among these patients slightly higher than in the general population in the same region during the study period (data from national seroprevalence survey of the general population in Catalonia in June 2020, 5.9% 5.71) [5]. During one year’s follow-up (Jan 2020-Jan 2021), the majority of infected patients showed mild/absence of COVID-19-related symptoms and only two (2/15; 13.3%) needed admission to hospital with respiratory disease. As far as we know, this is the first study focused on SARS-CoV-2 infection in paediatric patients with IEI.

Most IEI patients have direct or indirect impairment of some of the components of the anti-viral response, in most cases presenting viral infection susceptibility [8]; moreover, immunocompromising conditions have been associated with more severe outcomes with non-COVID-19 coronavirus infections in children [20]. Thus, IEI was initially listed as one theoretical risk factor for symptomatic/severe COVID-19. Our cohort (Table 1) included patients from 7/10 different IEI categories, the most frequent being combined immunodeficiency with syndromic features and humoral immune deficiencies, which are also the most frequent groups in current classifications. Thus, our cohort is representative of other large published cohorts [21].

Data obtained in our study show a slightly higher prevalence (10.7%; 7–13%) when compared to the general population in Catalonia in the same period with 5.9% (5.0%–7.1%), although IEI patients followed the same infection prevention recommendations as the general population, and even more strictly and sooner than officially recommended in some cases. To date, no data regarding the prevalence of COVID-19 among patients with IEI have been published against which we could compare our data.

Despite this higher prevalence, IEI patients from our cohort did not develop severe COVID-19 symptoms. Data from healthy children in Spain aged <2 years old, 2-4, 5-14, and 15-29 show that only 2.3%, 0.6%, 0.4%, and 1.2%, respectively were admitted to hospital, and only 10 deaths have been reported up to the end of April 2021 in patients <14 years old [22]. Despite the lack of information related specifically to adolescents, recent reports suggest that COVID-19 often presents a more severe course in adolescents than in younger children [23]. In our cohort, 2/15 (13.3%) were admitted to hospital, both adolescents (17 and 19 years old). Nevertheless, they did not suffer severe complications nor mortality, suggesting that their clinical evolution was closer to other healthy children and young adults than to older adults, in whom higher hospitalization and mortality rates (hospitalization/mortality rate in group age 60-69 is 13.9%/1.5%; 70-79% is 23.6 /5.2% and > 80 34%/ 16%) have been reported [23].

The available data regarding COVID-19 in IEI patients, mainly adults, are inconsistent. The European cohort, led by the ESID and published by Meyts and cols et al, as well as the experience of Israel, show good clinical courses [10,24]; the Italian experience with humoral deficiencies even suggests a possible protective factor for severe COVID-19 associated with X-linked- agammaglobulinemia or dominant negative STAT3 defects, probably because of its interference with IL-6 production [11–13]. In contrast, other experiences with larger cohorts suggest higher mortality rates and severity among patients with IEI [4,25].

In the majority of these cohorts, paediatric patients are under-represented. Of note, Delavari et al. reported on a cohort of 19 patients with IEI and COVID-19. The majority of them (84%) were < 20 years of age and 8/19 died, of whom 5 were younger than 20. Those data contrast with previous studies and the low mortality rate among young cases in the general population. The difference may arise from the fact that 10 of the 19 cases included were severe combined immunodeficiency or familial lymphohistiocytosis without HSCT [26]. Thus, it seems clear that IEIs are a wide and heterogeneous group of disorders for which SARS-CoV-2 susceptibility differs widely.

From the limited information available regarding IEI and COVID-19, it seems that certain immunodeficiencies carry a higher risk than others; specifically, CVID with dysregulation [14,25] and defects involving type 1 interferon pathways [15] have been associated with higher hospital admission, severity, and mortality. The reasons why CVID is related with higher mortality and severity remain unclear; the presence of underlying
morbidity such as chronic lung disease or the need for immunoglobulins, leading to more severe immunodeficiency status, have been proposed as important factors. In our cohort, the majority of patients presented a mild clinical course, even those suffering an IEI theoretically related to susceptibility to viral infections. To date only 3 cases of MyD88 deficiency, which had been reported not to be associated with susceptibility to viral infections, were siblings affected with MyD88 deficiency, which had been reported not to be associated with susceptibility to viral infections. Since the two patients from our cohort shown that IgA specific antibodies could grow early and strongly than IgM and IgG antibodies and concretely some of them focus in specific IgA antibodies: they have attributable to a higher ACE II concentration which seems to offer a protective effect on severe clinical SARS-CoV-2 infection, along with higher ‘trained’ innate immune system due to vaccines and other respiratory viral infections during infancy, which is especially relevant in paediatric IEI patients who have recurrent upper respiratory tract infections.

Finally, regarding the diagnostic test performed in our patients, all of our patients except two were diagnosed by serology test. Curiously, 2 patients were diagnosed only by SARS-CoV-2 specific IgA. Different studies have been published until now regarding the specific SARS-CoV-2 serology assays and their value as a diagnostic test for the infection, and concretely some of them focus in specific IgA antibodies: they have shown that IgA specific antibodies could grow early and strongly than IgM and IgG antibodies. Since the two patients from our cohort (patients 3 and 5; Table 2) that were considered infected only by positive IgA belong to the seroprevalence study (cross-sectional), it may be well that we detected COVID-19 infection during early stages, before IgG/M seroconversion. On the other hand, although none of them have humoral immunodeficiency they are immunodeficient patients, and this may have an impact on their antibody production.

In conclusion, in our cohort including moderate/severe children and young adults with IEI, the infection rate was slightly higher than that observed in the general population, despite patients’ following the same infection prevention recommendations. Even with this higher rate, no severe COVID-19 was observed; only 2 patients with MyD88 deficiency

### Table 2
Baseline and clinical characteristics of SARS-CoV-2 infected IEI patients.

| Age (years) | Gender | IEI | Chronic treatments | Positive household contacts | COVID-19 WHO classification* | Symptoms | Positive serologies | PCR | Specific COVID-19 treatment |
|------------|--------|-----|--------------------|-----------------------------|-----------------------------|----------|---------------------|-----|-----------------------|
| **Cross-sectional (January-June 2020)** |
| P1 13      | female | Jacobsen syndrome | - CVID pattern           | suspected                   | 1 | Cough               | IgG and IgA          | -  | no                    |
| P2 15      | female | Down syndrome     | - mod/severe lymphopenia | suspected                   | 1 | Asymptomatic        | IgG                 | -  | no                    |
| P3 11      | female | PGM3 deficiency   |                      | suspected                   | 1 | Fever and interstitial pneumonia | IgA              | -  | no                    |
| P4 17      | male   | Di George with mod/severe lymphopenia | STAT1GOF                   | no                          | 1 | Asymptomatic        | IgG                 | -  | no                    |
| P5 15      | male   | Hydroxy-chloroquine | Flucconazole              | no                          | 1 | Cough and upper airway congestion | IgA              | -  | no                    |
| P6 10      | male   | Jacobsen syndrome | - mod/severe lymphopenia | no                          | 1 | Cough and upper airway congestion | IgG and IgA         | -  | no                    |
| P7 5       | male   | Di George mod/severe lymphopenia |                      | no                          | 1 | Cough               | IgM                 | -  | no                    |
| **Patients collected from June 2020–January 2021** |
| P8 14      | female | CVID | Chronic granulomatous disease | no                          | 1 | Asymptomatic        | Negative IgG and IgM | +  | no                    |
| P9 22      | male   | Chronic granulomatous disease | SMZ-TMP | no                          | 1 | Asymptomatic        | IgG and IgM          | np | no                    |
| P10 8      | male   | XLA | IgRT | confirmed | 1 | Asymptomatic        | IgM                 | +  | no                    |
| P11 19     | male   | Ataxia telangiectasia | IgG and           | suspected                   | 1 | Fever, headache, and asthenia | negative IgM         | +  | no                    |
| P12 17     | female | CVID | no | suspected                   | 1 | Asymptomatic        | IgG and IgM          | +  | no                    |
| P13 16     | female | MyD88 deficiency | no | suspected                   | 2 | Fever, headache, and asthenia | Steroids            | +  | no                    |
| P14 19     | male   | MyD88 deficiency | no | suspected                   | 2 | Fever, headache, and asthenia, and hypoxic interstitial pneumonia | Steroids            | +  | no                    |
| P15 17     | male   | ALPS syndrome | no | no                          | 1 | Headache, upper airway congestion, odynophagia, taste and smell disturbances | Remdesivir Antibiotics |    | no                    |

mod/severe: moderate/severe; SMZ-TMP: sulfamethoxazole-trimethoprim; nv: non valuable; np: not performed.

SMZ-TMP: sulfamethoxazole-trimethoprim.
required hospital admission and both showed good clinical evolution. Among possible explanations, the absence of comorbidities linked to COVID-19 severity, the possibility that only certain IEI are really risk factors for developing severe COVID-19, and a possible protection caused by age < 21 should be mentioned. Studies with larger samples are needed to confirm the trend observed in this study. In the event that this observation is borne out, this could influence future prevention measures in this special population.

5. Conclusions

This is the first study focused on paediatric patients with IEI and the impact on COVID-19. Our data show a higher infection rate, but without clinical severity except in two patients with MyD88 deficiency, suggesting that other factors such as younger age, absence of comorbidity, and more highly ‘trained’ immunity due to greater exposure to viral respiratory infections in IEI patients might be more important determinants of COVID-19 outcome than the immune deficiency per se. In the event that these data are confirmed in larger paediatric IEI cohorts, these findings could have an impact on future SARS-CoV-2 infection prevention recommendations for this population.

Declarations of interest

None.

Appendix A. Appendices

Fig. A.1. Study design.

https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_355_COVID-19.pdf. Consulted 1st of March of 2021 (first case in Spain 31st of January; locked down period from 15th March to 21st June).

Funding source

This work was supported by the projects PI18/00223, PI19/00208 and PI21/00211 to LA, integrated in the Plan Nacional de I+D+i and co-financed by the ISCIII – Subdirección General de Evaluación y Fomento de la Investigación Sanitaria – and the Fondo Europeo de Desarrollo Regional (FEDER), by Pla Estratègic de Recerca i Innovació en Salut (PERIS), Departament de Salut, Generalitat de Catalunya (SLT006/17/00199 to LA), by a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (IN[17]_BBM_CLI_0357) to LA, by a 2017 Beca de Investigación de la Sociedad Española de Inmunología Clínica Alergología y Asma Pediátrica to LA, and by a 2021 Beca de Investigación de la Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica to ADM. CERCA Programme/Generalitat de Catalunya.

Acknowledgments

This work was also partially funded by Stavros Niarchos Foundation (SNF), Banco Santander, and other private donors of “KidsCorona platform” from Hospital Sant Joan de Déu.

https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_355_COVID-19.pdf. Consulted 1st of March of 2021 (first case in Spain 31st of January; locked down period from 15th March to 21st June).
Fig. A.2. Clinical description of two patients with moderate COVID-19.

In this figure the two patients with the more severe COVID-19 from our cohort are described. Both patients are siblings, with Myd88 deficiency, presenting both respiratory symptoms with an interstitial pneumonia. Curiously, the patient A, presented the worst analysis parameters while the patient B presented the worst clinical evolution needing oxygen.

BMI: Body mass index; *the lowest and highest values were observed at 3rd day of admission **only one blood analysis. min: minimum; max.: maximum.

Table A.1
Specific IEI included in the study (n = 65).

| IEI group | Number of patients and specific disease |
|-----------|----------------------------------------|
| Immunodeficiencies affecting cellular and humoral immunity | 7/65 (10.7%) |
| - 2 RFXANK SCID | |
| - 1 Hyper IgM CD40L | |
| - 1 CID | |
| - 3 idiopathic CD4+ lymphopenia | |
| Combined immunodeficiencies with associated syndromic features | 31/65 (47.7%) |
| - 1Kabuki syndrome | |
| - 5 Ataxia-telangiectasia | |
| - 10 CATCH22 | |
| - 2 Jacobsen syndrome | |
| - 3 Down syndrome | |
| - 1 Trico-hepato-enteric syndrome | |
| - 1 CHARGE syndrome | |
| - 2 Mitochondrial disease | |
| - 6 other syndromes | |
| Predominantly antibody deficiencies | 14/65 (20.6%) |

(continued on next page)


References

[1] J.F. Ludvigsson, Systematic review of COVID-19 in children show milder cases and a better prognosis than adults, Acta Paediatr. 109 (6) (2020) 1088–1095, https://doi.org/10.1111/apa.15297.

[2] Y. Jin, H. Yang, W. Ji, W. Wu, S. Chen, W. Zhang, G. Duan, Virology, epidemiology, pathogenesis and control of COVID-19, Viruses. 12 (4) (2020) 372, https://doi.org/10.3390/v12040372.

[3] L. Guo, L. Ren, S. Yang, M. Xiao, D. Chang, F. Yang, C.S. De la Cruz, Y. Wang, C. Wu, Y. Xiao, L. Zhang, L. Han, S. Dang, Y. Xu, Q.W. Yang, S.Y. Xu, H.D. Zhu, Y. C. Xu, Q. Jin, L. Sharma, L. Wang, J. Wang, Profiling early humoral response to diagnose novel coronavirus disease COVID-19, Clin. Infect. Dis. 71 (15) (2020) 778–785, https://doi.org/10.1093/cid/ciaa310.

[4] Ministerio de Sanidad. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/situacionActual . (Accessed 30 April 2021).

[5] Generalitat de Catalunya. Dades COVID. https://dadescovid.cat . (Accessed 30 April 2021).

[6] P.C.M. Williams, A.R. Howard-Jones, P. Hsu, P. Palasanthiran, P.E. Gray, B. McMullan, P.N. Britton, A.W. Bartlett, SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings, Pathology. 52 (7) 778–785, https://doi.org/10.1111/pat.13263.

[7] J. McMullan, P.N. Britton, A.W. Bartlett, SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings, Pathology. 52 (7) 778–785, https://doi.org/10.1111/pat.13263.

[8] F. Haerynck, P. Soler-Palacin, A. Martin-Nalda, T. Ozcelik, K.K. Yasar, S. Senoglu, S. Spaan, B. Boisson, S. Boisson-Dupuis, J. Bustamante, A. Puel, M.J. Ciancanelli, J. Mustillo, R.S. Abraham, S. Gupta, A. Ozen, E. Karakoc-Aydiner, S. Baris, A. Mustillo, R.S. Abraham, S. Gupta, A. Ozen, E. Karakoc-Aydiner, S. Baris, A. 2021). (Accessed 30 April 2021).

[9] C. Rydzymski Moderbacher, S.I. Ramirez, J.M. Dan, A. Griffoni, K.M. Hastie, E.B. Pathak, J.L. Salemi, N. Sobers, J. Menard, I.R. Hambleton, COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020, J. Public Health Manag. Pract. 26 (2020) 325–333, https://doi.org/10.1097/PHH.0000000000001190.

[10] E.B. Pathak, J.I. Salemi, N. Sobra, J. Menard, J.R. Hambleton, COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020, J. Public Health Manag. Pract. 26 (2020) 325–333, https://doi.org/10.1097/PHH.0000000000001190.

[11] B. Baronio, M. Giacomelli, R. Badolato, Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover, Pediatr. Allergy Immunol. 31 (5) (2020) 565–569, https://doi.org/10.1111/pai.13263.

[12] F. Freeman, M. Yamazaki-Nakashima, S. Scheffler-Mendoza, S. Espinosa-Padilla, A.R. Genney, S. Jolles, Y. Espinosa, M.C. Poli, C. Fieschi, F. Hauck, C. Cunningham-Rundles, N. Mahalou, the IUIS Committee of Inborn Errors of Immunity, K. Warnatz, K.E. Sullivan, S.G. Tangye, Coronavirus disease 2019 in patients with inborn errors of immunity: An international study, J. Allergy Clin. Immunol. 147 (2) (2021) 520–531, https://doi.org/10.1016/j.jaci.2020.09.010.

[13] I. Quinti, V. Lougaris, C. Millo, F. Cinetra, A. Pecoraro, I. Mezzaroma, C. Rizzuto, A. Plebani, A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia, J. Allergy Clin. Immunol. 146 (1) (2020) 211–213, e4, https://doi.org/10.1016/j.jaci.2020.04.013.

[14] A. Soresina, D. Moratto, M. Chiarini, C. Pailliol, G. Baresi, E. Foca, M. Bezzi, B. Baronio, M. Giacomelli, R. Badolato, Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover, Pediatr. Allergy Immunol. 31 (5) (2020) 565–569, https://doi.org/10.1111/pai.13263.

[15] H. Abanchian, N. Moazzen, M.S.D. Faroughi, N. Khalighi, M. Khoshkhi, M. H. Arelami, N.S. Motevalli Haghi, N. Rezaei, COVID-19 in a child with primary specific antibody deficiency, Clin. Case Rep. 9 (2) (2021) 755–758, https://doi.org/10.1002/ccr3.3643.

[16] H.E. Ho, S. Mathew, M.J. Peluso, C. Cunningham-Rundles, Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City, J. Allergy Clin Immunol Pract 9 (1) (2021) 490–493, e2, https://doi.org/10.1016/j.jaip.2020.09.052.

[17] Q. Zhang, P. Bastard, L. Liu, J. Le Pen, M. Moncada-Velez, J. Chen, M. Ogishi, S.A. Rawlings, J. Mateus, L. Ping, V. Tse, A. Frazier, R. Baric, B. Peters, D. Weiskopf, S. Belanger, R.K. Abbott, C. Kim, J. Choi, Y. Kato, E.G. Crotty, C. Kim, J. McMullan, P.N. Britton, A.W. Bartlett, SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings, Pathology. 52 (7) 778–785, https://doi.org/10.1111/pat.13263.

[18] N. Spaan, B. Boisson, S. Boisson-Dupuis, J. Bustamante, A. Puel, M.J. Ciancanelli, J. Mustillo, R.S. Abraham, S. Gupta, A. Ozen, E. Karakoc-Aydiner, S. Baris, A. 2021). (Accessed 30 April 2021).

Table A.1 (continued)

| IEI group | Number of patients and specific disease |
|-----------|---------------------------------------|
| 3 Bruton’s agammaglobulinemia | 11 CVID |
| 4/65 (6.1%) | 1 XIAP-like (no genetics) |
| 1 CTLA4 | 1 STAT3 GOF |
| 1 undefined severe disorder of immune dysregulation (no genetics) | 2 CDG |
| 6/65 (9.2%) | 1 WHIM syndrome (CXC4R4 GOF) |
| 3 CMC (STAT1 GOF) | 1 TLR3 deficiency |
| 1 Hyper IgE syndrome (PGM3) | 1/65 (1.5%) |
| 1 APLAD syndrome (PLCG2 deficiency) | |

SCID: severe combined immunodeficiency; CID: combined immunodeficiency; CVID: common variable immunodeficiency; CGD: chronic granulomatous disease; WHIM (warts, hypogammaglobulinemia, immunodeficiency, myelokatexis); CMC: chronic mucocutaneous candidiasis.

Table A.2

Definition of moderate/severe lymphopenia [18].

| CD4+ absolute count/μl | birth-11 months | 1-5 years | > 5 years |
|-------------------------|----------------|-----------|-----------|
| Moderate immunosuppression | 750–1499/15%–24% | 500–999/15%–24% | 200–499/15%–24% |
| Severe immunosuppression | <750/15% | <500/15%–24% | <200/15% |

*Definition of moderate/severe lymphopenia [18].*
